Approval

Ruoxinlin Anxiety Approval in China

China's National Medical Products Administration approved Luye Pharma's Ruoxinlin for generalized anxiety disorder, its second approved indication in China. In an eight-week phase III study, the company reported a response rate above 80% and a remission rate of approximately 50%, with a favorable overall safety profile. Ruoxinlin was previously approved in China for major depressive disorder in November 2022.

Written by Gosset from public sources. Source types: SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call